Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydrocortisone + fludrocortisone is a combination therapy used primarily for the treatment of adrenal insufficiency, such as Addison's disease and congenital adrenal hyperplasia. Hydrocortisone is a synthetic glucocorticoid that mimics cortisol, providing anti-inflammatory and immunosuppressive effects. Fludrocortisone is a synthetic mineralocorticoid structurally related to cortisol but with strong aldosterone-like activity, helping to regulate sodium retention and potassium excretion. The combination replaces both glucocorticoid and mineralocorticoid activity in patients whose adrenal glands do not produce sufficient endogenous corticosteroids. This dual replacement improves prognosis in conditions like catecholamine-resistant septic shock with relative adrenal insufficiency by supporting vascular responsiveness and fluid balance[5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydrocortisone + fludrocortisone.